Ataturk Universityâs DAYTAM strengthens Turkiyeâs pharmaceutical and industrial sectors

Anadolu/Anadolu via Getty Images

Leveraged Loans

Curium acquisition of Lantheus backed by $5.375B of debt financing

In addition to the debt financing, CapVest Partners, Curium’s current sponsor, is providing an equity commitment of $2.346 billion.

Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility.

The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administrative agent, while the PIK facility will be an additional facility under Curium Midco’s existing PIK agreement.

Curium earlier this month agreed to acquire Lantheus, a radiopharmaceutical-focused diagnostics company, for $102.50 per share in cash at closing, plus a contingent value right (CVR) of up to $12 per share in additional cash payments tied to commercial sales milestones through 2030, for total consideration of up to $114.50 per share and a total transaction value of up to $8 billion. In addition to the debt financing, CapVest Partners, Curium’s current sponsor, is providing an equity commitment of $2.346 billion. Closing is expected in H1 2027, subject to Lantheus shareholder approval and regulatory approvals.

Curium’s outstanding debt includes a $1.14 billion covenant-lite term loan B due July 2031 (S+300, 0% floor) and a €530 million TLB due July 2031 (E+350, 0% floor). In May, Curium closed a private credit loan led by CVC Credit that refinanced a prior loan with the lender.

Current corporate ratings are B-/B3/B, with stable outlooks, and TLB facility ratings are B-/B3/B+, with a recovery rating of 3 on the loan from both S&P Global Ratings and Fitch.

Lantheus has outstanding a $575 million issue of 2.625% convertible senior unsecured notes due December 2027.

Boston-based Curium is a global radiopharmaceutical company focused on the development, manufacturing and supply of diagnostic and therapeutic radiopharmaceuticals. CapVest, in November 2025, completed a recapitalization of Curium through a continuation vehicle, valuing the company at roughly $7 billion, including a minority investment from TPG Life Sciences Innovations. CapVest, which has backed the firm since 2017, remains the controlling shareholder.

Sign up for The Credit Pitch

Weekly coverage of US and European loans, bonds, private credit, and more.

Anadolu/Anadolu via Getty Images

Learn about our editorial standards.